Biohaven secures $500M licensing cash and FDA resubmission acceptance for Vyglxia
Biohaven Ltd. announced two exclusive licensing agreements that will provide up to $500 million in near‑term, non‑dilutive cash. The company also reported that the FDA has accepted its new‑drug‑application resubmission for Vyglxia in spinocerebellar ataxia, setting a user‑fee goal date in the first quarter of 2027. The deals include a $400 million cash consideration from SK Biopharmaceuticals and up to $100 million from Ono Pharmaceutical, while clinical programs for BHV‑1300 and BHV‑1400 remain on track.
Why it matters
The cash inflow strengthens Biohaven’s balance sheet and funds ongoing development without diluting shareholders. The FDA acceptance moves the Vyglxia program toward a potential approval timeline in early 2027, which could add a new revenue stream if successful.
Key facts
- 1The FDA accepted Biohaven’s new‑drug‑application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia and set a user‑fee goal date in 1Q27. prnewswire.com
- 2Biohaven entered an exclusive global license with SK Biopharmaceuticals for its Kv7 ion‑channel platform, providing $400 million in near‑term cash consideration. prnewswire.com
- 3Biohaven signed an exclusive license with Ono Pharmaceutical for its MoDE IgG degrader portfolio, with up to $100 million in near‑term payments, including $80 million received to date and a $20 million milestone payment anticipated within a year. prnewswire.com
- 4The Ono agreement also includes royalties of approximately twenty percent on net sales in the licensed territory. prnewswire.com
- 5More than 50 sites have been activated for enrollment in the pivotal Phase 3 trial of BHV‑1300 in Graves’ disease in the US and Canada. sec.gov
- 6Biohaven is on track to start the pivotal Phase 3 trial of BHV‑1400 in IgA nephropathy during 4Q 2026 across multiple regions. sec.gov
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.